Global

Newsroom

RSS feed

Media Enquiries

Sharon McHale
Sharon McHale
Senior Director Public Affairs
CSL Limited
Phone: +613 9389 1506
Mobile: +61 409 978 314
Email: sharon.mchale@csl.com.au
45 Poplar Rd, Parkville
Victoria 3052 Australia

30/04/2013
bioCSL Goes Back into Influenza Vaccine Production for Australia
bioCSL announced today that it has recently restarted production of influenza vaccine for the Australian market in response to higher than expected demand this season. More.

29/04/2013
bioCSL Awarded Major Vaccine Distribution Contracts
bioCSL has been selected by New South Wales Health (NSW Health) and the Western Australian Department of Health (WA DoH) to provide storage and distribution services for government funded vaccine programs. The contracts, awarded after separate tender processes, have a combined value of $6.8 million. More.

05/04/2013
CSL Half Year Report 2012-13
bioCSL has been selected by New South Wales Health (NSW Health) and the Western Australian Department of Health (WA DoH) to provide storage and distribution services for government funded vaccine programs. The contracts, awarded after separate tender processes, have a combined value of $6.8 million. More.

28/03/2013
New US$500 million Private Placement
CSL Limited (ASX:CSL) is pleased to announce that on 27 March 2013 it closed a new US$500m Private Placement in the US. More.

08/03/2013
Terms of Appointment of Managing Director and CEO
CSL Limited (ASX:CSL) has previously announced that Mr Paul Perreault will succeed Dr Brian McNamee as Managing Director and Chief Executive Officer of CSL from 1 July 2013. More.

13/02/2013
Half Year Results announcement for 2012/13
CSL Limited (ASX:CSL) today announced a net profit after tax of US$627 million for the six months ended 31 December 2012, up US$123 million or 24% on a reported basis when compared to the prior comparable period (PCP). Earnings per share grew 30%, benefiting from current and past capital management initiatives. More.

13/02/2013
Appointment of Paul Perreault as Executive Director
CSL Limited (ASX:CSL) is pleased to announce the appointment of Mr Paul Perreault to the CSL Limited Board as an Executive Director effective 13 February 2013. More.

13/02/2013
Change to 2013 Dividend Payment Dates
CSL Limited (ASX:CSL) is pleased to announce that, in line with its previous announcement on 17 December 2012 to bring forward the announcement of its Half Year and Full Year Results Announcements by one week, it will also bring forward the payment date of its interim and full year dividends by one week. More.

17/12/2012
2013 Half Year and Full Year Announcement Dates
CSL Limited (ASX:CSL) announced today that it has decided to bring forward the announcement of its Half Year and Full Year Results Announcements by one week. More.

27/11/2012
CSL Lifts Profit Guidance
CSL Limited (ASX:CSL) today announced a revised US Dollar profit outlook for fiscal 2013. The Company now expects net profit after tax to grow by approximately 20% at constant currency1, despite competitive business conditions. More.

05/11/2012
Novel Apolipoprotein A-I Therapy, CSL112, May Represent New Option for Reducing Recurrent Heart Attack Risk, Early CSL Studies Show
Infusions of a novel formulation of apolipoprotein A-I (apoA-I) – the main component of high-density lipoprotein (HDL) - rapidly increased the presence of key biomarkers associated with reverse cholesterol transport, a process by which cholesterol is removed from arteries and transported to the liver for clearance, according to data from a Phase 1 study sponsored by CSL Limited. More.

27/09/2012
CSL celebrates first anniversary of workplace childcare centre
CSL Limited today celebrated the first anniversary of its Thinking Kids Children’s Centre, an early childhood education and care centre at CSL’s Parkville site in Victoria. More.

20/06/2012
CSL Biotherapies provides update on Fluvax® investigation
CSL Biotherapies (CSL) today presented preliminary conclusions from its investigations into the cause of the unexpected adverse events associated with Fluvax® influenza vaccine in 2010. The presentation was made at the Public Health Association of Australia’s 13th National Immunisation Conference in Darwin. More.

>> Prior Archived Newsroom


 

Media Enquiries - CSL Limited
Sharon McHale
Senior Director Public Affairs
Phone: +613 9389 1506
Mobile: +61 409 978 314
Email: sharon.mchale@csl.com.au
45 Poplar Rd, Parkville
Victoria 3052
Australia